Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

Kidney International

Volumn 83, Issue 3, 2013, Pages 517-523

  Perkovic, Vlado ^a   Heerspink, Hiddo Lambers ^b   Chalmers, John ^a   Woodward, Mark ^a,c   Jun, Min ^a   Li, Qiang ^a   Macmahon, Stephen ^a,d   Cooper, Mark E ^e   Hamet, Pavel ^f   Marre, Michel ^g   Mogensen, Carl Erik ^h   Poulter, Neil ⁱ   Mancia, Giuseppe ^j   Cass, Alan ^a   Patel, Anushka ^a   Zoungas, Sophia ^a,k  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g BICHAT HOSPITAL   (France)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ ST MARY S HOSPITAL   (United Kingdom)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k MONASH UNIVERSITY   (Australia)

more..

Author keywords

blood pressure; cardiovascular events; chronic kidney disease; clinical trial; epidemiology and outcomes

Indexed keywords

CREATININE; GLICLAZIDE; HEMOGLOBIN A1C;

AGED; ALBUMINURIA; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

EID: 84874662499     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.401     Document Type: Article

References (31)

1. U.S. Renal Data System (2011). USRDS 2011 Annual Data Report: Chapter: Incidence, Prevalence, Patient Charateristics and Treatment Modalities. National Institutes of Health, National Institute of Diabetes and Kidney Diseases: Bethesda, MD, 2011
2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
3. Strippoli GF, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ 2004; 329: 828
4. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
5. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
6. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
7. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
8. DCCT Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
9. ADVANCE Study Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
10. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
11. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
12. Calvo G, de Andres-Trelles F. Albuminuria as a surrogate marker for drug development: A European Regulatory perspective. Kidney Int Suppl 2004; 92: S126-S127
13. Levey AS, Cattran D, Friedman A et al. Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-226
14. Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J 2010; 31: 2205-2208
15. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011; 20: 246-257
16. Colagiuri S, Dickinson A, Girgis S, Colagiuri R. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Diabetes Australia and the NHMRC: Canberra, 2009
17. American Diabetes Association. Standards of medical care in diabetes -2011. Diabetes Care 2011; 34(Suppl 1): S11-S61
18. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203
19. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430
20. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
21. de Boer IH, Sun W, Cleary PA et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376
22. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
23. Fioretto P, Steffes MW, Sutherland DE et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75
24. Berl T, Hunsicker LG, Lewis JB et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. (Summary for patients in Ann Intern Med. 2003;138(7):I43; PMID: 12667050). Ann Intern Med 2003; 138: 542-549
25. GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863
26. Yusuf S, Teo KK, Pogue J et al. Ontarget Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
27. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428
28. Heerspink HJL, Perkovic V, De Zeeuw D. Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials? Nephron Clin Pract 2011; 119: 195-199
29. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011; 58: 69-73
30. ADVANCE Study Group. Study rationale and design of ADVANCE: Action in diabetes and vascular disease -preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120
31. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154